Clinical Study of Rituximab for the Treatment for Idiopathic Membranous

Updated 05/10/2024

Status Recruiting

Clinical Trial Summary

To confirm the efficacy and safety of rituximab (genetical recombination) intravenously administered to idiopathic membranous nephropathy with nephrotic syndrome.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05914155
Study type	Interventional
Source	Nagoya University
Contact	Shoichi Maruyama, PhD, MD
Phone	+81527442192
Email	marus@med.nagoya-u.ac.jp
Status	Recruiting
Phase	Phase 3
Start date	June 24, 2023
Completion date	December 31, 2026

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT01129557` - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease	Phase 4
	Completed	`NCT00199628` - Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization
	Active, not recruiting	`NCT05656963` - The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
	Completed	`NCT04145440` - Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)	Phase 1/Phase 2
	Terminated	`NCT04154787` - Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy	Phase 2
	Completed	`NCT00404794` - A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis	Phase 3
	Completed	`NCT03880643` - Rituximab in Refractory Primary Membranous Nephropathy
	Not yet recruiting	`NCT05797051` - Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases
	Completed	`NCT00135967` - Mycophenolate Mofetil in Membranous Nephropathy	Phase 2/Phase 3
	Completed	`NCT00843856` - Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis	Phase 4
	Recruiting	`NCT01282073` - Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy	Phase 3
	Completed	`NCT00135954` - Treatment of Patients With Idiopathic Membranous Nephropathy	Phase 3
	Completed	`NCT01610492` - A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy	Phase 2
	Active, not recruiting	`NCT03018535` - Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy	Phase 3
	Completed	`NCT00404833` - Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental	Phase 3
	Withdrawn	`NCT01762852` - Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy	Phase 2